


26. (Amended) The method of claim 25 wherein the maytansinoid is DM1 having the structure



36. (Amended) The method of claim 34 wherein the second antibody is humanized antibody, huMAb4D5-8.

43. (Amended) The method of claim 42 wherein the unconjugated antibody is humanized antibody huMAb4D5-8 or humanized 2C4.

46. (Twice Amended) The method of claim 1 wherein said treatment has an improved objective response rate compared to treatment with huMAb4D5-8 alone.

47. (Twice Amended) The method of claim 1 wherein said treatment has a longer duration of response than treatment with huMAb4D5-8 alone.

48. (Twice Amended) The method of claim 1 wherein said treatment results in increased survival of the mammal treated compared with treatment with huMAb4D5-8 alone.